INTRAVENOUS BI 836826 IN COMBINATION WITH IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY, AND WHO ARE ELIGIBLE FOR TREATMENT WITH IBRUTINIB: